{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Congenital+Defects&page=71",
    "query": {
      "condition": "Congenital Defects",
      "page": 71
    },
    "page_size": 10
  },
  "pagination": {
    "page": 71,
    "page_size": 10,
    "total_count": 10850,
    "total_pages": 1085,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Congenital+Defects&page=72&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Congenital+Defects&page=70&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-21T01:17:02.108Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02079818",
      "title": "Visceral Artery Aneurysm Embolization by the Penumbra Ruby™ Coil System",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Visceral Artery Aneurysms",
        "Arteriovenous Malformations"
      ],
      "interventions": [
        {
          "name": "Penumbra Ruby Coil System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Penumbra Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 0,
      "start_date": "2017-06",
      "completion_date": "2018-09",
      "has_results": false,
      "last_update_posted_date": "2019-04-12",
      "last_synced_at": "2026-11-21T01:17:02.108Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02079818"
    },
    {
      "nct_id": "NCT05438290",
      "title": "DPCP to Treat Cutaneous Neurofibromas Associated With NF1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cutaneous Neurofibroma"
      ],
      "interventions": [
        {
          "name": "DPCP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nicholas Gulati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2022-09-14",
      "completion_date": "2023-05-17",
      "has_results": false,
      "last_update_posted_date": "2024-05-06",
      "last_synced_at": "2026-11-21T01:17:02.108Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05438290"
    },
    {
      "nct_id": "NCT02864082",
      "title": "A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Congenital Ichthyosis"
      ],
      "interventions": [
        {
          "name": "PAT-001, 0.1%",
          "type": "DRUG"
        },
        {
          "name": "PAT-001, 0.2%",
          "type": "DRUG"
        },
        {
          "name": "Vehicle for PAT-001 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Vehicle for PAT-001 0.2%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Patagonia Pharmaceuticals, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2017-03-08",
      "completion_date": "2018-12-04",
      "has_results": true,
      "last_update_posted_date": "2021-09-29",
      "last_synced_at": "2026-11-21T01:17:02.108Z",
      "location_count": 5,
      "location_summary": "San Diego, California • New Haven, Connecticut • Chicago, Illinois + 2 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02864082"
    },
    {
      "nct_id": "NCT04139018",
      "title": "Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hereditary Hemorrhagic Telangiectasia"
      ],
      "interventions": [
        {
          "name": "Timolol Gel",
          "type": "DRUG"
        },
        {
          "name": "Placebo Gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "20 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2019-10-20",
      "completion_date": "2020-05-20",
      "has_results": true,
      "last_update_posted_date": "2021-08-24",
      "last_synced_at": "2026-11-21T01:17:02.108Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04139018"
    },
    {
      "nct_id": "NCT02922413",
      "title": "Panhematin for Prevention of Acute Attacks of Porphyria",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Intermittent Porphyria",
        "Hereditary Coproporphyria",
        "Variegate Porphyria"
      ],
      "interventions": [
        {
          "name": "Hemin for injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "The University of Texas Medical Branch, Galveston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2015-10-30",
      "completion_date": "2023-12-27",
      "has_results": true,
      "last_update_posted_date": "2026-01-30",
      "last_synced_at": "2026-11-21T01:17:02.108Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02922413"
    },
    {
      "nct_id": "NCT05562713",
      "title": "CIC Behavioral Economics in Children With Spina Bifida",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Spina Bifida",
        "Neurogenic Bladder"
      ],
      "interventions": [
        {
          "name": "Present Bias without Loss Aversion",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Present Bias with Loss Aversion",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "4 Years to 12 Years"
      },
      "enrollment_count": 22,
      "start_date": "2023-08-01",
      "completion_date": "2024-04-18",
      "has_results": false,
      "last_update_posted_date": "2024-06-06",
      "last_synced_at": "2026-11-21T01:17:02.108Z",
      "location_count": 2,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05562713"
    },
    {
      "nct_id": "NCT02307513",
      "title": "A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Behçet's Syndrome"
      ],
      "interventions": [
        {
          "name": "Apremilast",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 207,
      "start_date": "2014-12-30",
      "completion_date": "2020-07-17",
      "has_results": true,
      "last_update_posted_date": "2021-07-22",
      "last_synced_at": "2026-11-21T01:17:02.108Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • Sacramento, California • Ormond Beach, Florida + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Ormond Beach",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02307513"
    },
    {
      "nct_id": "NCT04906460",
      "title": "Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "WVE-N531",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wave Life Sciences USA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "18 Years",
        "sex": "MALE",
        "summary": "4 Years to 18 Years · Male only"
      },
      "enrollment_count": 25,
      "start_date": "2021-09-28",
      "completion_date": "2027-04-24",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-11-21T01:17:02.108Z",
      "location_count": 2,
      "location_summary": "Little Rock, Arkansas • Atlanta, Georgia",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04906460"
    },
    {
      "nct_id": "NCT06335524",
      "title": "Infant-Maternal Partnership and Cognitive Training Study for Preterm Infants",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Child Development",
        "Infant Development",
        "Infant, Premature, Diseases"
      ],
      "interventions": [
        {
          "name": "Finger puppet",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Bookworm reading intervention training and routine EDI care.",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Week",
        "maximum_age": "17 Weeks",
        "sex": "ALL",
        "summary": "1 Week to 17 Weeks"
      },
      "enrollment_count": 188,
      "start_date": "2024-11-01",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-29",
      "last_synced_at": "2026-11-21T01:17:02.108Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06335524"
    },
    {
      "nct_id": "NCT05104723",
      "title": "Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Granulomatous Disease",
        "Inflammatory Gastrointestinal Disease",
        "Inflammatory Skin Disease",
        "Inflammatory Lung Disease"
      ],
      "interventions": [
        {
          "name": "XELJANZ (tofacitinib)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 10,
      "start_date": "2022-08-12",
      "completion_date": "2026-05-04",
      "has_results": false,
      "last_update_posted_date": "2026-05-07",
      "last_synced_at": "2026-11-21T01:17:02.108Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05104723"
    }
  ]
}